Robert Rosenson, MD: ARCHES-2 and Zodasiran in Mixed Hyperlipidemia; Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.

Media coverage

• Title	Robert Rosenson, MD: ARCHES-2 and Zodasiran in Mixed Hyperlipidemia; Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.
  Media name/outlet	Consultant Live
  Country/Territory	United States
  Date	30/05/24
  Persons	Robert Sidney Rosenson

• Title	Robert Rosenson, MD: ARCHES-2 and Zodasiran in Mixed Hyperlipidemia
  Media name/outlet	HCP Live
  Country/Territory	United States
  Date	30/05/24
  Persons	Robert Sidney Rosenson